Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis

Taha Azad; Reza Rezaei; Abera Surendran; Ragunath Singaravelu; Stephen Boulton; Jaahnavi Dave; John C Bell; Carolina S Ilkow

doi:10.3390/cancers12082042

Hippo Signaling Pathway as a Central Mediator of Receptors Tyrosine Kinases (RTKs) in Tumorigenesis

Cancers (Basel). 2020 Jul 24;12(8):2042. doi: 10.3390/cancers12082042.

Authors

Taha Azad^{1

2}, Reza Rezaei^{1

2}, Abera Surendran^{1

2}, Ragunath Singaravelu^{1

2}, Stephen Boulton^{1

2}, Jaahnavi Dave^{1

2}, John C Bell^{1

2}, Carolina S Ilkow^{1

2}

Affiliations

¹ Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
² Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

Abstract

The Hippo pathway plays a critical role in tissue and organ growth under normal physiological conditions, and its dysregulation in malignant growth has made it an attractive target for therapeutic intervention in the fight against cancer. To date, its complex signaling mechanisms have made it difficult to identify strong therapeutic candidates. Hippo signaling is largely carried out by two main activated signaling pathways involving receptor tyrosine kinases (RTKs)-the RTK/RAS/PI3K and the RTK-RAS-MAPK pathways. However, several RTKs have also been shown to regulate this pathway to engage downstream Hippo effectors and ultimately influence cell proliferation. In this text, we attempt to review the diverse RTK signaling pathways that influence Hippo signaling in the context of oncogenesis.

Keywords: Hippo signaling; TAZ; YAP; receptor tyrosine kinases (RTKs).

Publication types

Review

Abstract

Publication types

Grants and funding